BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Biotech Bay

  Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

  Vivani Medical, Inc. announced that Company CEO Adam Mendelsohn, Ph.D. has been invited to participate at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.

  June 14, 2023

   · 

  6 min read
• Drug Development

  Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor

  Ventyx Biosciences, Inc. announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system -penetrant NLRP3 inhibitor.

  June 14, 2023

   · 

  5 min read
• Drug Development

  Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

  Nurix Therapeutics, Inc. announced the presentation of clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127, which are being evaluated in ongoing Phase 1 clinical trials in patients with relapsed/refractory B cell malignancies.

  June 14, 2023

   · 

  13 min read